

Cabrini Research – Consumer story

Ms Sophie Hill

After being diagnosed for CLL, Ms Sophie Hill chose Cabrini upon the recommendation of her general practitioner, where she was assured that she would receive the best possible care. This was confirmed upon meeting Associate Professor Kenealy, who “has been a highly knowledgeable and empathetic haematologist.” During a routine appointment, Ms Hill was informed that her blood results indicated it was time to begin treatment and that there was a clinical trial suitable for her CLL.



Eager to improve her condition and contribute to medical research, Sophie welcomed the opportunity to participate.

“I welcomed the opportunity to take part in the trial, in the hope that my condition would improve,” reflected Ms Hill, “[and]

I was also keen to play a part in supporting research and development of treatment options for other CLL patients.”

An initial adverse reaction to obinutuzumab required her to be admitted to hospital for one week. However, she felt reassured having been told that potential side effects were manageable and that she had the option to cease treatment any time. Throughout each step of the trial, Ms Hill felt exceptionally supported by the entire Cabrini team, including her trial coordinator, Demis Balamatsias.

Now in remission, she describes the outcome as being “brilliant... I feel very fortunate to have had the opportunity to participate, when so many people around the world don’t have access to good and affordable healthcare. It’s my understanding that advances are happening steadily in the blood cancer sphere, and I am pleased to have played a part in the improvement and development of treatment options for CLL.”